Neurosoft Bio creates ultra‑soft, elastic brain‑computer interface devices that match neural tissue mechanics, allowing minimally invasive implantation through tiny burr holes and reducing scar tissue, hematoma, and brain compression. Their platform combines foldable, ultra‑thin electrode arrays with AI‑driven signal processing to extract biomarkers, optimize neuromodulation, and decode motor or speech intentions for diagnostic and therapeutic use in neurological disorders.
Funding
$7.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ICPCPL+1Founders
Product
Problem
Current brain-computer interface (BCI) technologies are rigid, relatively thick, and require invasive surgical procedures, leading to scar tissue formation, subdural hematomas, brain compression, and limited long‑term stability. These issues restrict the clinical use of BCIs for monitoring, treating, and restoring functions in patients with neurological disorders.
Solution
Neurosoft Bio develops ultra‑soft, elastic brain interfaces that match the mechanical properties of neural tissue, reducing the mismatch that causes tissue damage. Their devices are 1,000–100,000 times softer and 3–5 times thinner than conventional electrodes, enabling folding, unfolding, and insertion through minimal openings such as burr holes. The platform integrates artificial‑intelligence algorithms to extract biomarkers, optimize neuromodulation, and decode motor or speech intentions in real time. By combining minimally invasive hardware with AI‑driven analytics, Neurosoft Bio aims to provide safer, longer‑lasting BCIs for both diagnostic and therapeutic applications across a range of neurological conditions.
Target Audience
Primary customers are neurosurgeons, neurologists, and clinical research centers developing implantable neurotechnologies for epilepsy, tinnitus, and severe motor impairments, as well as medical device manufacturers seeking soft BCI components.
Features
- Soft, stretchable subdural electrode arrays (SOFT ECoG™) with enhanced conformability to brain surfaces, reducing scar formation and risk of hematoma
- Foldable, ultra‑thin device architecture (MINDZ™) that can be deployed through a burr hole, minimizing craniotomy size and surgical trauma
- Closed‑loop neuromodulation system (SOFT TINNIT™) for targeted treatment of severe tinnitus using real‑time brain signal feedback
- AI‑enabled signal processing pipeline that detects biomarkers, optimizes stimulation parameters, and decodes motor/speech intentions for assistive exosuits (Synapsuit)
- Semiconductor‑grade manufacturing allowing customizable electrode designs, high density, and reduced pitch for precise neural mapping
- Compatibility with intra‑operative and sub‑chronic (up to 30 days) use cases, supporting epilepsy focus localization and brain mapping during resections